-
Chronic hypertension and adverse pregnancy outcomes: a cohort study.
Panaitescu AM, Syngelaki A, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:228-235. pdf -
Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:203-9. pdf -
Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:194-202. pdf -
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
Bujold E, Roberge S, Nicolaides KH.
Prenat Diagn 2014;34:642-8. pdf -
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013;33:215-23. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
Maternal racial origin and adverse pregnancy outcome: a cohort study.
Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:278-85. -
Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester trisomy 21 maternal serum.
Lopez MF, Kuppusamy R, Sarracino DA, Prakash A, Athanas M, Krastins B, Rezai T, Sutton JN, Peterman S, Nicolaides K.
J Proteome Res 2011;10:133-42. -
Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study.
Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, Lun FM, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au-Yeung SK, Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM.
BMJ 2011;342:c7401. -
Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women.
Bombard AT, Akolekar R, Farkas DH, Vanagtmael AL, Aquino F, Oeth P, Nicolaides KH.
Prenat Diagn 2011;31:802-8. -
Fetal RHD Genotyping in Maternal Plasma at 11-13 Weeks of Gestation.
Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicolaides KH.
Fetal Diagn Ther 2011;29:301-6. -
Synergy of Total PLAC4 RNA concentration and measurement of the RNA single-nucleotide polymorphism allelic ratio for the noninvasive prenatal detection of Trisomy 21.
Tsui NB, Akolekar R, Chiu RW, Chow KC, Leung TY, Lau TK, Nicolaides KH, Lo YM.
Clin Chem 2010;56:73-81. -
Epigenetic-genetic chromosome dosage approach for fetal trisomy 21 detection using an autosomal genetic reference marker.
Tong YK, Chiu RW, Akolekar R, Leung TY, Lau TK, Nicolaides KH, Lo YM.
PLoS One 2010;5:e15244. -
Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of Trisomy 21.
Chiu RW, Sun H, Akolekar R, Clouser C, Lee C, McKernan K, Zhou D, Nicolaides KH, Lo YM.
Clin Chem 2010;56:459-63. -
Detection of trisomy 21 by quantitative mass spectrometric analysis of single-nucleotide polymorphisms.
Tsui NB, Chiu RW, Ding C, El-Sheikhah A, Leung TN, Lau TK, Nicolaides KH, Lo YM.
Clin Chem 2005;51:2358-62. -
Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler.
Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH.
Prenat Diagn 2005;25:949-53. -
The role of uterine artery Doppler in predicting adverse pregnancy outcome.
Papageorghiou AT, Yu CK, Nicolaides KH.
Best Pract Res Clin Obstet Gynaecol 2004;18:383-96. -
Second-trimester uterine artery Doppler screening in unselected populations: a review.
Papageorghiou AT, Yu CK, Cicero S, Bower S, Nicolaides KH.
J Matern Fetal Neonatal Med 2002;12:78-88. -
Individualized risk assessment for adverse pregnancy outcome by uterine artery Doppler at 23 weeks.
Lees C, Parra M, Missfelder-Lobos H, Morgans A, Fletcher O, Nicolaides KH.
Obstet Gynecol 2001;98:369-73. -
One-stage screening for pregnancy complications by color doppler assessment of the uterine arteries at 23 weeks' gestation.
Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH.
Obstet Gynecol 2000;96:559-64.